Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315653 · ClinicalTrials.gov registry record
Survivin Urine mRNA Assay Risk of Bladder Cancer Study
A clinical trial of Bladder Cancer, sponsored by Fujirebio Diagnostics.
- Completed
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT00315653 is a study of Bladder Cancer that has completed, run by Fujirebio Diagnostics. The registered enrollment target is 600 participants, below the 12,750-participant average among 175 other Bladder Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00315653, a study of Bladder Cancer, has completed, sponsored by Fujirebio Diagnostics.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to evaluate the ability of urinary Survivin mRNA measurement to estimate the risk of bladder cancer at the time of cystoscopy in subjects with no prior history of bladder cancer presenting with microscopic or macroscopic hematuria.
Conditions Studied
Study Locations (1)
Pennsylvania
- Fujirebio Diagnostics, Inc - Malvern
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00315653
The ClinicalTrials.gov registry entry for NCT00315653 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,750-participant average among 175 other Bladder Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Fujirebio Diagnostics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00315653 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00315653 about?
NCT00315653 is a clinical study titled "Survivin Urine mRNA Assay Risk of Bladder Cancer Study". The purpose of this clinical trial is to evaluate the ability of urinary Survivin mRNA measurement to estimate the risk of bladder cancer at the time of cystoscopy in subjects with no prior history of bladder cancer presenting with microscopic or macroscopic hematuria.
What is the current status of trial NCT00315653?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2005-09. Estimated completion is 2007-11.
What conditions does trial NCT00315653 study?
This clinical trial studies the following conditions: Bladder Cancer.
Who is sponsoring clinical trial NCT00315653?
This trial is sponsored by Fujirebio Diagnostics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00315653 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.